ARTICLE | Clinical News
Glactiv sitagliptin regulatory update
August 8, 2011 7:00 AM UTC
In May, Japan approved Glactiv sitagliptin to treat Type II diabetes in combination with alpha-glucosidase inhibitors. The dipeptidyl peptidase-4 (DPP-4) inhibitor is already marketed in Japan to tre...